6 recruiting, 3 completed, 1 withdrawn. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 6, Completed 3, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Soft Tissue Sarcoma Adult: new trials by email Literature Review of Soft Tissue Sarcoma Adult trials Research Report on Soft Tissue Sarcoma Adult
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall Moderately hypofractionated neoadjuvant radiotherapy - Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma (Excluding GIST) | Phase 2 | Recruiting | Centre Oscar Lambret | 135 | 2026-07-21 | 2026-07-23 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 110 | 2026-01-26 | 2026-01-28 |
| Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Association of pembrolizumab + cabozantinib - Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma | Phase 2 | Recruiting | Institut Bergonié | 119 | 2022-04-25 | 2025-10-07 |
| Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Propranolol, Pembrolizumab - Soft Tissue Sarcoma Adult, Angiosarcoma | Phase 2 | Recruiting | Niels Junker | 80 | 2021-08-17 | 2023-07-27 |
| Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Retifanlimab, Gemcitabine, Docetaxel - Soft Tissue Sarcoma, Sarcoma,Soft Tissue | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 98 | 2020-09-29 | 2026-09-08 |
| Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study Association of Nivolumab + Relatlimab, Nivolumab - Soft Tissue Sarcoma Adult, Advanced Cancer | Phase 2 | Completed | Institut Bergonié | 68 | 2020-02-27 | 2026-04-21 |
| Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma Anlotinib Hydrochloride, Placebo Oral Tablet - Soft Tissue Sarcoma Adult, High Grade Sarcoma | Phase 2 | Completed | Fudan University | 88 | 2019-05-13 | 2025-05-14 |
| Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma Eribulin, Lenvatinib - Leiomyosarcoma, Liposarcoma | Phase 1 / Phase 2 | Completed | National Taiwan University Hospital | 30 | 2018-07-12 | 2025-12-05 |
| Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial Apatinib - Soft Tissue Sarcoma Adult, Advanced Cancer | Phase 2 | Withdrawn | Peking University People's Hospital | 2017-04-01 | 2020-05-19 |
Sarcoma (9) · Histiocytoma, Malignant Fibrous (4) · Leiomyosarcoma (3) · Liposarcoma (3) · Dermatofibrosarcoma (2) · Sarcoma, Synovial (2) · Hemangiosarcoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Osteosarcoma (1) · Sarcoma, Ewing (1) · Tertiary Lymphoid Structures (1)
Neoplasms by Histologic Type (9) · Neoplasms, Connective and Soft Tissue (9) · Neoplasms (8) · Histiocytoma (4) · Neoplasms, Connective Tissue (4) · Neoplasms, Fibrous Tissue (4) · Neoplasms, Adipose Tissue (3) · Neoplasms, Muscle Tissue (3) · Fibrosarcoma (2) · Neoplasms, Bone Tissue (1) · Neoplasms, Vascular Tissue (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1)
Docetaxel (1) · Gemcitabine (1) · Nivolumab (1) · Propranolol (1) · Quality of Life (1) · apatinib (1) · cabozantinib (1) · eribulin (1) · lenvatinib (1) · pembrolizumab (1) · relatlimab (1) · spartalizumab (1)
Institut Bergonié (2) · Oslo University Hospital (2) · Centre Oscar Lambret (1) · Fudan University (1) · Memorial Sloan Kettering Cancer Center (1) · National Taiwan University Hospital (1) · Niels Junker (1) · Peking University People's Hospital (1)
France (3) · Norway (3) · China (2) · Denmark (1) · Sweden (1) · Taiwan (1) · United States (1)
Ivar Hompland, MD, PhD (2) · Kjetil Boye, MD, PhD (2) · Niels Junker, MD, PhD (1) · Sandra D'Angelo, MD (1) · Wangjun Yan (1) · Wei Guo, M.D.Ph.D. (1) · Wei-Wu Chen, MD (1)
2019 (1)